Free Trial
NASDAQ:XOMA

XOMA Q1 2023 Earnings Report

XOMA logo
$21.18 +0.65 (+3.17%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$21.22 +0.05 (+0.21%)
As of 04/17/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA EPS Results

Actual EPS
-$0.98
Consensus EPS
-$0.50
Beat/Miss
Missed by -$0.48
One Year Ago EPS
N/A

XOMA Revenue Results

Actual Revenue
$0.44 million
Expected Revenue
$0.90 million
Beat/Miss
Missed by -$460.00 thousand
YoY Revenue Growth
N/A

XOMA Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Tuesday, May 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

XOMA's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

XOMA Earnings Headlines

Xoma initiated with a Buy at Benchmark
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More XOMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XOMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XOMA and other key companies, straight to your email.

About XOMA

XOMA (NASDAQ:XOMA) operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

View XOMA Profile

More Earnings Resources from MarketBeat